Screening for melanoma has been advocated for many years because early detection and excision have been regarded as the most important measure to lower mortality from that neoplasm. In the past decade, concern has been raised by epidemiologists that screening might result in excision chiefly of "inconsequential cancer," i.e., melanomas that would never have progressed into life-threatening tumors, a phenomenon referred to by the misleading term "overdiagnosis." Without any firm evidence, that speculation has been embraced worldwide, and incipient melanomas have been trivialized. At the same time, efforts at early detection of melanoma have continued and have resulted in biopsy of pigmented lesions at a progressively earlier stage, such as lesions with a diameter of only 2, 3, or 4 mm. Those tiny lesions often lack sufficient criteria for clinical and histopathologic diagnosis, the result being true overdiagnoses, i.e., misdiagnoses of melanocytic nevi as melanoma. This is especially true if available criteria for histopathologic diagnosis are diminuished even further by incomplete excision of lesions. The reliability of histopathologic diagnosis is far higher in excisional biopsies of lesions that were given some more time to develop changes that make them recognizable. Biopsy of pigmented lesions with a diameter of 6 mm has been found to result in a far higher yield of melanomas. In addition to better clinical judgment, slight postponement of biopsies bears the promise of substantial improvement of the reliability of histopathologic diagnosis, and of alleviating true overdiagnoses.
ABSTRACT

Introduction of Screening for Melanoma
Because of direct visibility and detectability at an early stage and usually slow growth, melanoma came to be viewed as a "model for cancer education and prevention" and an "ideal screening tumor" [12, 13] . Criteria for diseases qualifylate 19th century, any active treatment of melanoma was discouraged. For example, Moriz Kaposi cautioned that, "according to experience, extirpation even of the very first nodules cannot arrest further progress. Hence, the procedure is carried out only rarely, and the very first symptom of pigmented cancer is regarded as an ominous sign of a rapidly deleterious course" [1] . In 1933, Guido Miescher noted that surgical treatment for melanomas was "more and more abandoned at least for primary tumors because the danger of acute dissemination is doubtlessly high, and cases with acute aggravation following surgical procedures have been observed repeatedly" [2] . As late as in the 1960s, those fears had not been overcome. As stated in Gottron's handbook of dermatalogy and venerology, "until recently, management followed the principle of 'noli me tangere' that regarded any therapeutic procedure as malpractice. Today, treatment has entered an active stage but an agreed-upon therapeutic approach has not emerged" [3] .
Establishment of Clinical and Histopathologic Criteria for Recognition of Incipient Melanoma
The last decades of the 20th century witnessed a radical paradigm shift. Therapeutic restraints were replaced by the conviction that melanomas must be detected and exstirpated as early as possible, not as an exophytic nodule but as a tiny papule, not as a papule but as a macule. For decades, the macular stage of melanoma had been misinterpreted as a benign nevus that, according to accepted wisdom, underwent "malignant transformation" when a nodule of melanoma developed on it. For example, in 1953, Allen and Spitz described typical histopathologic signs of melanoma in situ, including: "(1) the general features of nuclear anaplasia such as hyperchromatism, increase in nuclear and nucleolar size, irregular nuclear vacuolization, and mitotic figures; (2) subepithelial inflammatory reaction consisting prepoderantly of lymphocytes; and (3) cytoplasmic vacuolization and fine melanin pigmentation reaching to the uppermost layers, that is, to the stratum granulosum and stratum corneum." They concluded, nonetheless, that "the decision as to whether or not a given lesion is to be diagnosed an active junctional nevus or a melanocarcinoma must ... depend on this single fact: THE PRESENCE OR ABSENCE OF DERMAL INVASION" [4] .
It took many years to realize that the vast majority of melanomas start in the anatomic structure that harbors melanocytes physiologically, namely, the epidermis, and that they can be recognized there. In a histopathologic study of melanoma in 1958, Lane et al described melanoma in situ under the name "purely junctional malignant melanoma." at primary prevention, i.e., prevention of the development of skin cancer, but also included efforts at secondary prevention, i.e., early detection and treatment. Several other campaigns followed [18, 19] . After a continuous rise in the incidence of age-specific melanoma for many decades, together, these campaigns likely were responsible for a decrease in the age-specific melanoma incidence in Australia, the first country worldwide to note a decrease. However, those effects are still shrouded by an absolute increase in the number of detected melanomas due to demographic aging [20] ( Figure 1 (10) Case-finding should be a continuing process and not a 'once and for all' project" [14] . Those criteria were subsequently supplemented and specified: the disease must have serious consequences and a high prevalence in order to justify screening efforts, and it must progress slowly and not be immediately life threatening [15, 16] . All those conditions are fulfilled by melanoma. [33] . When patients with early-stage melanomas came to consultation hours following the first German melanoma campaign in Giessen in the early 1980s, they were said to "probably owe their life to the campaign" [25] , and this [23, 24] . In Germany, the Giessen Melanoma Group started an educa- The results of that study contributed to the decision to implement populationbased skin cancer screening in Germany. Since mid-2008, free skin cancer screening is offered to all adults over 34 years of age every two years under the scope of public health insurances [28] .
Most studies about melanoma screening failed to detect a positive effect on mortality, and in Germany, the positive trend could not be substantiated in follow-up studies [29] . However, mortality remained at least relatively stable despite a marked increase in the incidence of melanoma. The latter was attributed to factors such as greater sun exposure during recreational activities, use of solariums, travel to tropical countries, and depletion of the ozone layer of the stratosphere [28, 30, 31] . [45]; the "Menzies method" that considered symmetry and monochromacity to be exclusion criteria for melanoma [46] ; a "7-point checklist" with three major and four minor criteria [47] ; a simplified "3-point checklist" [48] ; and the CASH algorithm that emphasized the importance of "color, architecture, symmetry, and homogeneity" for the assessment of melanocytic neoplasms [49] . Moreover, dermatoscopy enabled assessment of the development of lesions by following their natural course-far more precise a technique than conventional clinical examination or anamnestic data [50] .
Irrespective of the recognition scheme, dermatoscopy has the potential of enhancing the sensitivity and specificity of clinical diagnosis of melanoma substantially. However, it requires some experience, and without it, it may lead to undesired results [51] .
In order to overcome subjectivity and lack of experience Those numbers, however, have little significance because they depend strongly on the experience of the investigator and, especially, on the type of lesions examined. At very early stages, diagnosis is far less precise than in more advanced lesions, no matter which technique is employed.
Increase in the Number of Biopsies
The rationale for the use of adjunctive techniques for clinical diagnosis is the desire to reduce the frequency of biopsies for suspicious pigmented lesions. In fact, numerous studies have demonstrated a decrease in biopsies following dermatoscopic assessment of pigmented lesions. However, some studies also
Improvement of Methods for Early Clinical Recognition of Melanoma
Those considerations led to enhanced efforts at early detection of melanoma. The latter included not only educational campaigns and screening examinations but also improvement of clinical diagnosis. Clinical examination of the skin by a trained physician fulfilled the screening requirement of "a suitable test or examination ... acceptable to the population" [14] , but sensitivity and specificity were limited; most studies revealed a sensitivity of about 80% and a specificity of about 70% [34] [35] [36] . The ABCD criteria were criticized because many nevi and seborrheic keratoses fulfilled them, and they did not encompass the early stage of nodular melanomas [37] .
For the latter, change of a pigmented lesion was the most important identifying feature. This led to supplementation of the ABCD rule by another letter, namely, "E" for "enlargement," "elevation," or "evolving." The latter term came to be preferred because it included any type of change [38] .
In order to detect changes of moles in patients with myriad pigmented lesions, total body photography was introduced in 1988, rendering possible a comparison with the previous state at each new consultation [39] .
In addition to the ABCDE rule, other formulas were advanced for clinical detection of melanomas, such as the "three Cs" ("color, contour, change") or the "Glasgow 7-point checklist" of 1990 that included, as major criteria, change in size, change in shape, and change in color, along with four minor criteria, namely, diameter ≥ 7 mm, inflammation, crusting or bleeding, and sensory change [40] . Because of its more complex nature, the "7-point checklist" did not become as popular and widely used as the ABCDE rule [41] .
A criterion not pertaining to the individual lesion is the "ugly duckling sign." First described in 1998, the sign implies that a pigmented lesion differing from all other lesions of a given patient is likely to be a melanoma [42] . The importance of that "intrapatient comparative analysis" has been substantiated by several studies [43] .
In addition to refinement of criteria for clinical diagnosis of melanoma, several technical advances enhanced precision of diagnosis. Most important was the introduction of the dermatoscope that enabled the surface of lesions to be studied in ten-fold magnification and with reduced scatter of light (application of fluid enables immediate contact of the lens to the skin surface). Hence, anatomic structures could be assessed down to the papillary dermis, and the distribution of pigment and vessels could be assessed far better than by the naked eye. Among the criteria established for dermatoscopy were assessment of different dermatoscopic patterns in "pattern analysis" [44] ; the "ABCD rule of dermatoscopy" that assessed asymmetry, borders, coloration, and "different structural components" according to a point rational scheme has resulted in a significant decrease of biopsy rates [60] . On the other hand, if a lesion shows changes during follow-up, this alone may prompt a biopsy to be performed-although less than 10% of changing lesions have been found to be melanomas [61] .
The number of nevi excised for each melanoma has been referred to as the "number needed to treat" and varies significantly in different studies; in a recent review numbers ranged between 4 and 29.9 [62] . The lower numbers may reflect the ratio in specialized centers but, in general, the higher numbers are probably closer to reality. In our own material, i.e., specimens examined in a big dermatopathology laboratory in Germany under the conditions of population-based skin cancer screening, the "number needed to treat" was 36.4 in three successive months of 2016. Epidemiologists are right to deplore that "biopsy samples are taken from hundreds of thousands of benign lesions ... In addition to needless morbidity, these interventions cost billions of dollars" [63] .
The substantial increase in biopsies was associated not only with an increase in the number of excised nevi but also of melanomas. The latter paralleled the rise in biopsies.
For example, in the United States, the number of biopsies increased between 1986 and 2001 by 154% and the number reported the opposite, namely, an increase in the number of lesions found to be suspicious dermatoscopically, compared to examination of them with the naked eye, that were found to be nevi histopathologically [56] . Likewise, data for confocal laser microscopy are contradictory. Some studies reported a significant decrease in biopsy rates [57] , whereas others found that the enhanced sensitivity of diagnosis of melanoma was associated with a decrease in specificity that resulted in biopsy of melanocytic nevi [58] . The same obtains for multispectral analysis [59] . One reason may be the occasional pres- A B C mas that would never have been noticed had they not been biopsied, implies the assumption that such melanomas also existed in the past without being treated and without resulting in higher morbidity and mortality. There are two possible explanations for that assumption. First, patients could have died of other causes before being bothered by their melanoma. Considering the advanced age of many patients with melanoma, that explanation is plausible. However, it does not explain the rise in the incidence of melanoma in children and young adults. If there were also melanomas in that age group that were never diagnosed and that never caused any trouble, they must have regressed spontaneously [68] .
The second explanation, spontaneous regression, is also That some melanomas "would never have developed into a clinically manifest tumour" is beyond dispute [67] .
However, to attribute the rise in the incidence of melanomas entirely to that phenomenon is just as one-sided as the tale of melanomas by 140% [63] . The parallel increase in biopsies and melanomas raised doubts concerning the tale of a "melanoma epidemic" that had been accepted wholesale for many years. The "incredibly rising incidence of malignant melanoma" [64] suddenly seemed to be incredible. A moderate rise in the incidence could be expected, if only because of increased longevity, but the dramatic increase seemed to be artificial and could be explained by a variety of other factors, such as increased reporting of melanomas to tumor registries and more reliable criteria for histopathologic diagnosis [65] . 
Failure of Melanoma to Develop into a "Clinically Manifest Tumor"
The hypothesis that the rise in the incidence of melanoma is caused primarily by "inconsequential cancer," i.e., melano-cytic nevi [50] . A study of 50 incipient melanomas followed dermatoscopically demonstrated a mean growth rate of 5.3 mm 2 per year [72] . Following incomplete removal of melanomas, recurrences are common, probably even the rule, a characteristic that caused melanomas to become the most frequent source of medical malpractice suits in the United States [73] .
Curtailment of Screening for a Potentially Life Threatening Tumor
Nonetheless, the hypothesis that the increased incidence of melanoma is "largely the result of increased diagnostic scrutiny and not an increase in the incidence of disease" [66] has found wide acceptance and has resulted in demands to curtail diagnostic scrutiny. In recent years, it has been suggested by epidemiologists that "screening guidelines should be revised to lower the chance of detection of ... inconsequential cancers with the same energy traditionally used to increase the sensitivity of screening tests" [63] . The cost of population-based screening for melanoma has been criticized, and it is estimated that 25,000 screening examinations are necessary to prevent a single death from melanoma, whereas other cancers show a far more favorable ratio, of a true "melanoma epidemic." Obviously, various factors play a role: an increase in detection and treatment melanomas that would have progressed and caused death in the absence of treatment, an increase in melanomas that would have remained "inconsequential" without such measures, and a real rise in the incidence of melanoma. That the latter exists is suggested by an increase in the number of thick melanomas in populations not participating in cancer screening [70] . Moreover, only a real rise in the incidence of melanoma explains the sustained high mortality rates because it is fallacious to assume that excision of many more melanomas at an early stage has no beneficial effect at all.
After all, we are not entirely ignorant about how mela- of an oxymoron" [79] , and Juan Rosai, in 2008, spoke of it as an "obsolete, untenable concept" [80] .
Although Clark himself had been among the first to emphasize that most melanomas do not arise in association with a nevus, that "the junction nevus has no formal histogenetic relationship to malignant melanoma," and that "most malignant melanomas pass through a long phase of superficial growth during which the process differs in appearance from junctional nevi" [81] , he subsequently presented melanoma as a model for the theory of multistep carcinogenesis, according to which malignant neoplasms arise from "precursor lesions" through accruing genetic alterations and came "to view melanocytic neoplasia as a paradigm for all neoplastic systems" [82] . In 1984, Clark and coworkers postulated a stepwise "tumor progression" from the "common acquired melanocytic nevus" via nevi with increasing "melanocytic dysplasia" to primary and metastatic melanoma. The "dysplastic nevus" was said to be the "histogenetic precursor of melanoma," and early stages of melanoma, including thin invasive lesions, were claimed not to be fully malignant because the authors "hypothesized that such tumors do not have competence for metastases," the latter being conferred to them through additional genetic alterations that launched melanoma into the "vertical growth phase" [82] . Incipient melanomas that fulfilled all histopathologic criteria for diagnosis were no longer diagnosed as melanoma but as nevi with "severe dysplasia" in order to adhere to the concept of tumor progression through successive "precursor lesions" [83] .
That old concept has been reanimated recently by the including dysplastic nevi, it was referred to as a "precursor lesion" and was distinguished explicitly from melanoma [84] .
Some authors even contended that in-situ melanomas are biologically distinct from invasive melanoma and that they are a different type of neoplasm affecting other age groups and different anatomic sites, and "not in themselves ... precursor lesions, but perhaps ... instead markers for increased risk of development of invasive melanomas" [85] . The tendency to deny the malignant nature of incipient melanomas coalesced with speculations concerning "overdiagnosis" of melanoma in precarious fashion-precarious because it may be dangerous to trivialize melanoma in situ. In-situ melanomas are no less melanomas than the same type of lesion at a slightly later stage. Their appearance, clinically and histopathologically, is identical to the macular component of advanced melanomas, e.g., only 800 examinations are necessary arithmetically to prevent one fatality in colon carcinoma [74] .
Accordingly, it has been suggested that screening be con- by intensifying education and screening of the whole population may not lead any longer to a strong improvement of prognosis" [75] . In fact, numerous studies have shown that the majority of melanomas are self-detected or detected by family members [76] [77] [78] . Because of direct visibility, screening for skin lesions is less urgent than for neoplasms such as colon carcinoma that cannot be noticed at an early stage by patients themselves.
Denial of the Malignant Nature of Melanoma at an Early Stage
The unhesitant acceptance of the speculation that the rise in melanoma incidence is caused primarily by removal of basically harmless lesions, and the dominant role that speculation or "inconsequential cancer." It is the very purpose of screening to detect and to remove "inconsequential" lesions in order to prevent them from becoming "consequential." Nonetheless, the logic of screening was turned upside-down by arguing that melanoma in situ cannot cause death and, therefore, is not malignant. For example, Clark, in 1990, referred to melanoma in situ as "a contradiction in terms, the prototype [88] . There is no marker that allows one to predict future behavior reliably, and such as marker will probably never emerge because behavior is not only determined by the lesion itself but by many unrelated factors, such as the immune response to it. In patients of advanced age, it may be justifiable to ignore a melanoma, but it is risky if one cannot gauge how much lifetime they have left. To count on spontaneous regression of melanoma in young and middle-aged patients would be negligent.
The Problem of "True" Overdiagnosis: Misdiagnosis of Nevi as Melanoma
In addition to death of patients from other causes and complete regression, there is yet another explanation for "melanomas" that "would never have developed into a clinically manifest tumour," namely, overdiagnosis-not "overdiagnosis" by epidemiologists but overdiagnosis in the traditional meaning of that term, i.e., misdiagnosis of melanocytic nevi as melanoma. Such overdiagnoses probably contribute substantially to the alleged rise in the incidence of melanoma [89, 90] .
Although diagnosis of melanoma is usually reliable thanks to numerous well-established criteria, there are exceptions. Lesions may also regress, but occasional regression of incipient melanomas does not militate against malignancy; spontaneous regression has also been reported in cases of melanoma with disseminated metastases [86] . In early lesions, that phenomenon is doubtlessly more common, but experience suggests that complete regression is an exception rather than the rule. At an early stage, there is usually no urgency in diagnosis, and lesions can be followed clinically for some time until the diagnosis can be made with confidence. However, at least in young patients, one cannot expect untreated melanomas to remain "inconsequential" for their lifetime. And even if a substantial share of melanomas currently detected early on would remain "inconsequential," early diagnosis and treatment cannot be discarded as superfluous as long as the future course cannot be foretold. Although epidemiologists have demanded "to focus on distinguishing indolent from aggressive disease" [87] and to reserve the designation "cancer" for "lesions with a reasonable likelihood of lethal progression if left untreated" [32] , no prescription has been offered on how to accomplish this. Even Welch conceded that "the conundrum in overdiagnosis is that clinicians can never know who is overdiagnosed at the time of cancer diagnosis" of melanoma in situ: pathologists employed different criteria for diagnosis in different areas of the country [92] . In a study of melanomas measuring 4 mm in diameter or less, only half were unanimously diagnosed as melanoma upon review by each of three dermatopathologists. The authors suggested adopting "a 'consensus diagnosis' approach among histopathologists, because these lesions have no true gold standard" [93] .
Incomplete Excision as an Important Cause of Overdiagnosis of Melanoma
The reliability of histopathologic diagnosis is diminished even further if lesions are not excised completely because, in that as an embryo at an early stage does not allow for distinction between male and female or between mouse and man. [Copyright: ©2018 Weyers.] Figure 9D . The lesion was probably excised completely, but it comes close to one lateral margin. Incomplete excision cannot be excluded. If this is a nevus, excision of it qualifies as "overtreatment" in the first place. Because a melanoma in situ cannot be ruled out, and the lesion may have been excised incompletely, a re-excision was performed, probably "double overtreatment." [Copyright: ©2018 Weyers.] excision. Not uncommonly, only fragments of epithelium are provided. The most likely explanation for that phenomenon is a low degree of suspicion on the part of clinicians because lesions of that size also lack clinical criteria for malignancy.
With a lesion considered to be probably benign, physicians may flinch from taking a generous biopsy and may attach greater importance to a favorable cosmetic result. Furthermore, the generous execution of biopsies-with biopsies being taken from lesions measuring only 2 or 3 mm in diameter-often leads to removal of many lesions and attempts to perform biopsies as simply and quickly as possible. The diligence attached to each biopsy, and the appraisal of the importance of diligence, are lower than with a more reserved approach.
Diagnosed "Too Early"
In other words, the formula of "the earlier, the better" that has replaced the old conviction of noli me tangere cannot be accepted without reservation. There is also such a thing as In cases lacking sufficient criteria for diagnosis, this is a strong incentive to err on the malignant side [89, 90] .
Of course, histopathologists may choose to acknowledge uncertainty and abstain from a specific diagnosis. In general, however, there is no fallback for them, as for clinicians who, in the case of doubt, perform a biopsy and delegate responsibility to the histopathologist. Traditionally, histopathology is considered to be the "gold standard" for the diagnosis of that, in principle, should be those most suitable for complete lesions, and if a small, rapidly growing firm papule is noted, it should be biopsied without delay, especially if pigment can be detected dermatoscopically, even if it is smaller than 6 mm in diameter [99, 100] .
There may also be other reasons to deviate from the rule to refrain from biopsies in lesions smaller than 6 mm in diameter. If dermatoscopy, confocal laser microscopy or other techniques reveal findings highly suggestive of malignancy, histopathologic evaluation is warranted. In such cases, however, histopathologists should be alerted to the high degree of suspicion because histopathologic criteria for malignancy may drag behind clinical ones. As long as histopathologic examination serves as a gold standard for diagnosis of melanocytic neoplasms, and very small melanomas "have no true gold standard" histopathologically in a substantial proportion of cases [93] , biopsy of small pigmented lesions should not be the rule but an exception.
If clinicians follow pigmented lesions until they develop obvious signs of malignancy or reach a diameter of 6 mm, the reliability of histopathologic diagnosis can be improved substantially. Moreover, a less generous approach to biopsy might result in more diligence devoted to that procedure, further enhancing the reliability of diagnosis. By allowing pigmented lesions to play themselves out until they reach a stage that makes them recognizable and enables an unequivocal diagnosis to be made in the vast majority of cases, overdiagnosis can be curtailed and management of patients improved substantially.
